Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.55 |
| ▸ | ACACA | Q13085 | 1/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | RARA | P10276 | 1/20 | 0.52 |
| ▸ | RARB | P10826 | 1/20 | 0.52 |
| ▸ | RARG | P13631 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19131259 | 0.88 | SMN1; SMN2 (0.64) | MITFTP53NCOA3TSHRLMNA | |
| SCHEMBL7448852 | 0.85 | ACACB (0.58) | ACACBACACARARARARBRARG | |
| SCHEMBL12171137 | 0.85 | ALDH1A1 (0.58) | MITFTP53NCOA3RARBTSHR | |
| SCHEMBL22530488 | 0.84 | TSHR (0.49) | MITFTP53NCOA3RARARARB | |
| SCHEMBL7835051 | 0.84 | NOTUM (0.68) | MITFTP53NCOA3RARARARB | |
| SCHEMBL22442352 | 0.83 | TSHR (0.59) | TP53TSHRLMNAATMNOTUM | |
| SCHEMBL25299060 | 0.82 | NPC1 (0.58) | TSHRNOTUMSMPD1ALDH1A1 | |
| SCHEMBL31362818 | 0.82 | NPC1 (0.58) | TSHRNOTUMSMPD1ALDH1A1 | |
| SCHEMBL27147499 | 0.82 | TSHR (0.57) | MITFTP53NCOA3RARARARB | |
| SCHEMBL6112858 | 0.81 | ACACB (0.59) | ACACBACACAMITFTP53NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10711027-B2 | DNA polymerase beta inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190202853-A1 | DNA POLYMERASE BETA INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2019-07-04 | — | — | US | disclosed |
| US-8324250-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711027-B2 | DNA polymerase beta inhibitors | POLB, POLH, POLN | ACACB 1047/4885ACACA 1550/4885MITF 2936/4885 |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | ACACB 4264/4885ACACA 4464/4885MITF 731/4885 |
| US-20190202853-A1 | DNA POLYMERASE BETA INHIBITORS | POLB, POLH, POLN | ACACB 1047/4885ACACA 1550/4885MITF 2936/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | ACACB 4264/4885ACACA 4464/4885MITF 731/4885 |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HTR3A, OPRL1, OPRK1 | ACACB 4325/4885ACACA 4398/4885MITF 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.